Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2012-05-10 Management Reports
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Q1 Report 2012
Management Reports Classification · 99% confidence The document is explicitly titled "Management Report of the First Quarter 2012" and contains detailed operational performance reviews, updates on discovery alliances (EVT Execute, EVT Integrate, EVT Innovate), acquisition updates, and confirmed financial guidance for the remainder of 2012. This structure—a comprehensive review of a specific interim period (Q1) including operational details and management commentary—is characteristic of an Interim/Quarterly Report (IR). It is too detailed to be a simple Earnings Release (ER) and is not the full annual filing (10-K). Since it contains management's detailed explanation of results and outlook, it aligns closely with the definition of an Interim/Quarterly Report (IR), although it also contains elements of a Management Report (MDA). Given the comprehensive financial and operational review for a specific interim period, IR is the most appropriate primary classification.
2012-05-10 German
Evotec AG and 4-Antibody AG form strategic collaboration to innovate antibody selection
Regulatory Filings Classification · 100% confidence The document is a press release dated May 9, 2012, announcing a 'strategic collaboration agreement' between Evotec AG and 4-Antibody AG regarding antibody discovery and development services. It details the terms, technology integration, and expected benefits. This type of announcement, which details a business partnership or alliance rather than routine financial results (ER, IR) or mandatory regulatory filings (10-K, DEF 14A), fits best under a general business update or regulatory announcement category. Since it is a specific business development announcement disseminated via a news service (DGAP), and it doesn't fit perfectly into the other specific categories like M&A (TAR) or Financing (CAP), the most appropriate classification is the general Regulatory Filings/News category (RNS), which often serves as a catch-all for significant, non-standard corporate news releases.
2012-05-09 English
Evotec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 14.06.2012 in Hamburg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 99% confidence The document is titled 'Bekanntmachung der Einberufung zur Hauptversammlung am 14.06.2012' (Announcement of the Convocation to the Annual General Meeting on 14.06.2012). It explicitly lists the agenda items ('Tagesordnung') for the 'ordentlichen Hauptversammlung 2012' (Ordinary Annual General Meeting 2012). This content directly relates to the formal meeting of shareholders and the proposals to be voted upon, which aligns perfectly with the definition of AGM Information (AGM-R). Although it mentions the presentation of the annual financial statements (Item 1), the primary purpose and structure of the document is the official notice and agenda for the AGM.
2012-05-07 German
Evotec to Report First Quarter Results on 10 May 2012
Report Publication Announcement Classification · 99% confidence The document is a short press release dated May 4, 2012, announcing that Evotec AG will report its financial results for the first quarter of 2012 on May 10, 2012. It provides details for an accompanying conference call and webcast. Since this document is an announcement about the *release* of financial results (which would be the ER or IR document) and not the results themselves, and given its short nature and focus on publication timing, it fits the definition of a Report Publication Announcement (RPA). It is not the full earnings release (ER) or the interim report (IR).
2012-05-04 English
Investor Presentation 2012
Investor Presentation Classification · 99% confidence The document text contains an investment recommendation ("BUY"), a price target, a preview of quarterly financial results ("1Q/12 preview"), detailed historical and forecasted financial tables (Profit and loss account), and extensive disclaimers typical of a third-party financial research report prepared by an analyst firm (Close Brothers Seydler Research AG). This content structure—analysis, forecast, and disclaimer—is characteristic of an Investor Presentation or a detailed research report, but given the specific definitions, it most closely aligns with an Investor Presentation (IP) which often includes detailed financial models and strategic outlooks, or potentially a Management Report (MDA) if it were directly from the company. However, since it is explicitly a research report from an external analyst firm, and it contains detailed financial projections and strategic commentary, 'Investor Presentation' (IP) is the best fit among the provided options for detailed, forward-looking analysis distributed to investors, even though it's not a slide deck. If 'Research Report' were an option, it would be chosen. Given the choices, 'IP' covers detailed analysis intended for investors. It is not an Earnings Release (ER) as it's a preview/analysis, nor is it a formal regulatory filing like 10-K or IR.
2012-05-04 English
Evotec AG announces multi-year agreement with The United States Environmental Protection Agency (EPA)
Environmental & Social Information Classification · 99% confidence The document is a short press release dated May 3, 2012, announcing a multi-year agreement (a contract) between Evotec AG and the United States Environmental Protection Agency (EPA) regarding compound management services. This announcement details a new business contract and its financial value (up to EUR7.7 million). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). It describes a significant business development, which often falls under general corporate news. Since there is no specific category for 'New Contract Announcement' or 'Business Development,' and it is not a formal financial report, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is disseminated via a news service (DGAP) and serves as a general corporate announcement. Reviewing the definitions: - Not 10-K, AR, IR, ER, MDA (not a financial report). - Not MANG (no board change). - Not DIRS, DVA, DLST, DIV, SHA, POS (no share/vote/dividend activity). - Not CT (not a transcript). - Not CAP (it's a service contract, not primary financing/fundraising). - Not LTR (not a legal proceeding). - It is a general corporate news item disseminated via a regulatory news service (DGAP). Given the options, RNS (Regulatory Filings/General Regulatory Announcements) is the best fit for a non-standard, material business announcement that doesn't fit the highly specific financial/governance categories.
2012-05-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.